https://www.gosh.nhs.uk/our-research/our-research-infrastructure/nihr-great-ormond-street-hospital-brc/brc-news/gene-therapy-trial-patients-fanconi-anaemia-open-gosh/
Gene therapy trial for patients with Fanconi anaemia to open at GOSH
22 Mar 2016, 5:24 p.m.
A clinical trial is to open at Great Ormond Street Hospital (GOSH) that will test the use of gene therapy during transplantation for the treatment of young people with Fanconi anaemia. The trial will be led by Dr Claire Booth, Dr Phil Ancliff and Professor Adrian Thrasher – who is the Gene, stem and cellular therapies Theme Lead at the Great Ormond Street BRC.
Fanconi anaemia is a life-limiting, inherited haematological disorder which causes bone marrow failure in childhood as well as other serious complications. Children can be treated with a bone marrow transplant but the success of this procedure depends on finding a well matched donor for the patient.
The clinical trial due to open at GOSH in the coming months will assess whether gene therapy could offer hope to children lacking a suitable donor for transplant.
Researchers will make use of the BRC-funded GMP facility to genetically modify the patient’s own stem cells during the trial.
NIHR launches £13.7m investment into brain tumour research
The National Institute for Health and Care Research (NIHR) has announced a £13.7 million investment that will support ground-breaking research to develop novel brain tumour treatments in the UK.
New consortium aims to help improve care for arthritis patients
A new UK-led research group, including Great Ormond Street Hospital and University College London, aims to improve the lives of children, young people and adults with arthritis by defining for the first time what being in ‘remission’ from arthritis truly
Update for patients and families on industrial action - December 2025
As you may be aware, some of our Resident Doctors will be taking part in planned industrial action from 7am on Wednesday 17 December to 7am on Monday 22 December.
‘Ready-made’ T-cell gene therapy tackles ‘incurable’ T-Cell leukaemia
A groundbreaking new treatment using gene-edited immune cells, developed at GOSH and UCL has shown promising results in helping children and adults fight a rare and aggressive cancer